Thus, we performed MDM2 downregulation by siRNA in p53-null cells, specifically in lung adenocarcinoma H1299 cells, and in HIPK2-null (HIPK2-Cas9) HeLa cells, obtained by CRISPR/Cas9 technology [28] (Fig. S1). This evidence concerns the gene HIPK2 and lung adenocarcinoma.